Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.45 |
| ▸ | RAB9A | P51151 | 10/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769835 | 0.87 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL3707910 | 0.77 | CHRNA7 (0.44) | CHRNA7POLBCHRNB4CHRNA3 | |
| SCHEMBL391952 | 0.75 | CHRNA7 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1CHRNA7 | |
| SCHEMBL12274238 | 0.73 | CHRNA7 (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1CHRNA7 | |
| Fumaric Acid SCHEMBL767250 | 0.71 | CHRNA7 (0.48) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| Fumaric Acid SCHEMBL391501 | 0.68 | CHRNA7 (0.55) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1395946 | 0.66 | CHRNA7 (0.65) | CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1769897 | 0.66 | CHRNA7 (0.62) | NPC1RAB9AMAPTCHRNA7CHRNB4 | |
| SCHEMBL24653524 | 0.65 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL30622710 | 0.65 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106042-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-01-31 | — | — | US | claimed |
| US-20110105478-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | claimed |
| EP-2257550-A1 | NOVEL 1,4-DIAZA-BICYCLOÝ3.2.2¨NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch A/S (DK) | 2010-12-08 | — | — | EP | claimed |
| WO-2009112460-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | WO | claimed |
| US-8106042-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-01-31 | — | — | US | disclosed |
| US-20110105478-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2257550-A1 | NOVEL 1,4-DIAZA-BICYCLOÝ3.2.2¨NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch A/S (DK) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009112460-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105478-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNA2, CHRNA4 | NPC1 2278/4885RAB9A 3627/4885SMN1; SMN2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.